Watch Professor John Kane discuss the value of using a long-acting injectable (LAI) earlier for the treatment of schizophrenia and how to help patients better understand the benefits to improve acceptance.
Abilify Maintena PBS Information: Authority required (STREAMLINED). Code: 4246 for schizophrenia.
This product is not listed on the PBS for the treatment of bipolar 1 disorder.
Please review Approved Product Information before prescribing.
Product Information is available by calling Lundbeck on 1300 721 277 or by clicking:
Abilify Maintena is a registered trademark of Otsuka Pharmaceutical Co., Ltd. Abilify Maintena is co-commercialised by Lundbeck Australia and Otsuka Australia Pharmaceutical Pty Limited.
